USSN 09/768,080 Page 2

## LISTING OF THE CLAIMS

09:35

The following is a marked-up version the Claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) with instructions and markings showing changes made herein to the previous version of record of the Claims. Underlining denotes added text while strikeout denotes deleted text.

## Claims 1-7. (Cancelled)

- 8. (Previously amended) A variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that said variant of said polypeptide produces a reduced immunogenic response in an individual than said polypeptide of interest, wherein said T-cell epitope is altered by having a terminal portion of said polypeptide of interest comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of said polypeptide of interest wherein said homolog does not comprise a T-cell epitope identical to said replaced epitope, and wherein said polypeptide of interest is an enzyme.
- 9. (Previously Amended) The variant of claim 8 wherein said variant comprises at least one less T-cell epitope than said polypeptide of interest.
- 10. (Previously Amended) The variant of claim 8 wherein said variant comprises at least two less T-cell epitopes than said polypeptide of interest.

Claims 11-13. (Cancelled)

- 14. (Previously Added) The variant of claim 8, wherein the polypeptide of interest and the homolog of said polypeptide are proteases.
- 15. (Previously Added) The variant of claim 14, wherein said protease is a subtilisin.

Claims 16-27. (Cancelled)